Tci Wealth Advisors, Inc. Immuno Gen, Inc. Transaction History

Tci Wealth Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 19, 2022	BUY	$3.15 - $5.76 $3,584 - $6,554	1,138 New	1,138 $5,000
Q1 2022 Apr 29, 2022	SELL	$4.26 - $7.48 $2,926 - $5,138	-687 Closed	0 $0
Q4 2021 Jan 24, 2022	BUY	$4.75 - $7.5 $736 - $1,162	155 Added 29.14%	687 $5,000
Q3 2021 Oct 29, 2021	BUY	$5.02 - $6.59 $2,670 - $3,505	532 New	532 $3,000
Q2 2021 Aug 02, 2021	SELL	$5.79 - $8.6 $1,302 - $1,935	-225 Closed	0 $0
Q1 2021 Apr 29, 2021	SELL	$6.5 - $10.53 $83,037 - $134,520	-12,775 Reduced 98.27%	225 $2,000
Q3 2018 Nov 02, 2018	SELL	$8.6 - $11.26 $8,600 - $11,260	-1,000 Reduced 7.14%	13,000 $123,000
Q2 2018 Jul 27, 2018	BUY	$9.52 - $12.15 $38,080 - $48,600	4,000 Added 40.0%	14,000 $136,000
Q1 2018 Apr 30, 2018	BUY	$6.7 - $12.95 $40,200 - $77,700	6,000 Added 150.0%	10,000 $105,000
Q4 2017 Feb 01, 2018	BUY	$5.07 - $7.92 $20,280 - $31,680	4,000	4,000 $26,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.